Research Labs

Physician-scientist Yu Chen studies the role of transcription factors that are critical for prostate cancer development.

Physician-scientist Emily Cheng studies the molecular mechanisms of cell death and their implications in tumorigenesis, tumor-microenvironment interactions, targeted therapy, and immunotherapy.

Physician-scientist Nai-Kong Cheung focuses on engineering antibodies and immune cells to treat both solid tumors and liquid tumors in children.

Physician-scientist Ping Chi studies genetic and epigenetic mechanisms of transcriptional regulation by oncogenic factors in GIST, MPNST, melanoma and other solid tumors.

The Chiosis lab uses a unique chemical biology approach to understand, diagnose, and treat cellular processes associated with chronic molecular stress, with the ultimate goal of developing novel therapeutic options for use in the clinic.

Computational chemist John Chodera uses statistical mechanics, molecular modeling, and automated biophysical experiments to help identify new potential therapeutics and investigate mechanisms of drug resistance in cancer.

The Choi Lab develops new synthetic biology tools to study cell-fate decisions in development.

Jonathan Coleman is a physician-scientist focused on translational research, cancer genomics, and patient-derived organoid models in the study of urologic malignancies. Ongoing work includes the development of local ablative therapies, their influence on the tumor microenvironment, and implications for therapy response.

Physician-scientist Aimee Crago studies mechanisms by which common genomic events drive initiation and progression of soft tissue tumors.

Arvin Dar’s lab develops chemical tools and probes to explore disease mechanisms and the structural biology of cancer targets.